In plain terms

The claim being assessed: Correcting chronic cerebrospinal venous insufficiency with venoplasty improves multiple-sclerosis disability and disease activity.

Where the evidence stands: Β — Association only. The pattern is real and repeatable, but nobody has shown it causes anything.

What this mechanism does: The evidence reviewed does not show this mechanism causing the outcome. That does not show it has no effect.

Strongest evidence for it: Preregistered primary-SC3 aggregation returns Β: meaningful flow/MRI evidence is retained, but clinical benefit is not demonstrated and sham improvement supplies a more parsimonious explanation for uncontrolled subjective response. A single Step11 downgrade from the Γ mechanistic/proxy starting point is explicit. Weakest-link aggregation would return Α because SC1 universal reproducibility/specificity fails; procedural injury Ε is separate and cannot determine a benefit score.

What decisive evidence would look like

In plain terms, researchers would change the proposed cause, confirm it changed as intended, and measure a meaningful health outcome while checking other explanations. The result should be able to support or count against the claim.

Relative explanatory fit: Alternative ranked ahead

What this review means

Sham-controlled venoplasty has not demonstrated MS disability benefit; a positive MRI reanalysis remains a bounded lead, while objective vascular and device complications establish that treatment can cause harm.

Implications for health and treatment: Preregistered primary-SC3 aggregation returns Β: meaningful flow/MRI evidence is retained, but clinical benefit is not demonstrated and sham improvement supplies a more parsimonious explanation for uncontrolled subjective response. A single Step11 downgrade from the Γ mechanistic/proxy starting point is explicit. Weakest-link aggregation would return Α because SC1 universal reproducibility/specificity fails; procedural injury Ε is separate and cannot determine a benefit score.

Limits for individual care: 69 primary reports with 8 selected partial-body examinations; density, heterogeneous controls and incomplete access set the confidence, not correctness. The grade applies to the exact registered claim; stronger findings for narrower subclaims remain separate. No complete-paper audit or blinded calibration is claimed. This educational review does not establish an individual treatment recommendation.

Medical information notice: This review provides general health information, not medical advice. It cannot diagnose a condition or replace an individual discussion with a qualified clinician.

Source checking used bounded original primary abstract passages/status records and selected original partial-body passages. No complete-abstract or complete-paper audit, or independent scientific peer review, is claimed. Detailed access counts and limitations appear in the review.

A low grade is not an accusation. It means the causal work has not been done yet, which is the ordinary state of most actively studied mechanisms in biology.

At a glance

Sub-claims assessed separately

Full assessment

From here the review is written for a technical reader: caps and thresholds, competing models, the independence basis, and the citation ledger.

Sources: 69 primary reports; claims: 74; verified: 74; unverified: 0. Verification is bounded attribution. Access: 8 partial-body and 61 bounded abstract/status examinations. Literature cutoff: 2026-10-12; source examination UTC date: 2026-10-12. No complete-paper audit or blinded calibration claimed.

Adversarial review: Generated by Sol 6.1; adversarially reviewed by Claude Opus 5.5 (Anthropic) on 2026-10-14. 8 corrections applied (see ADVERSARIAL REVIEW AND APPROVAL). Status: Approved as revised.

AT A GLANCE

Sham-controlled venoplasty has not demonstrated MS disability benefit; a positive MRI reanalysis remains a bounded lead, while objective vascular and device complications establish that treatment can cause harm.

Deciding experiment: If a scientifically and ethically justified study is contemplated, prospectively fix anatomical/pressure entry criteria and MS stage, verify sustained flow correction, randomize balloon venoplasty versus convincing sham with stable usual therapy and adequate clinical power, and test prespecified functional/relapse outcomes alongside MRI without conditioning on post-treatment responders.

Belief versus evidence: Preregistered primary-SC3 aggregation returns Β: meaningful flow/MRI evidence is retained, but clinical benefit is not demonstrated and sham improvement supplies a more parsimonious explanation for uncontrolled subjective response. A single Step11 downgrade from the Γ mechanistic/proxy starting point is explicit. Weakest-link aggregation would return Α because SC1 universal reproducibility/specificity fails; procedural injury Ε is separate and cannot determine a benefit score.

Best-supported rival: Expectation, regression and treatment selection. The Canadian randomized sham trial (PMID 30266886) best distinguishes intervention-specific benefit from nonspecific subjective response: both arms improve transiently but clinical endpoints do not separate. It does not establish diagnostic artifact by itself; sibling-controlled venography (PMID 24119384) supplies the separate physiological-variation contrast.

COMPETING MECHANISTIC MODELS

Rank 1: Expectation, regression and treatment selection (Ε). Uncontrolled symptom improvement can arise from nonspecific procedural response and selective treatment seeking. Canadian sham and venoplasty arms both improved transiently while objective endpoints did not differ; later registry benefits waned. These sources do not prove every subjective response is placebo or exclude a small biological MRI effect.

Rank 2: Physiological variation and operator-dependent diagnosis (Ε). Normal calibre/flow variation and acquisition or interpretation differences account for many CCSVI classifications. Sibling-controlled venography shows common narrowing; trained-reader studies and spontaneous/hydration classification changes identify context dependence. Real lesions and positive blinded M-mode findings remain; no exclusive artifact account explains every measurement.

Rank 3: Inflammatory MS with secondary vascular changes (Β). Inflammatory demyelination can coexist with secondary or age-related vascular changes. Early MS without detected CCSVI, duration/age relationships and rat ligation without demyelination separate vascular proxies from the MS sequence. The reviewed vascular corpus does not independently prove all immunological MS causes or establish reverse causation for every vein.

Rank 4: CCSVI is a treatable driver of MS (Β). Venous obstruction drives inflammatory pathology and its correction improves disability and activity. Original open-label improvements, pressure/flow responses, positive diagnostic originals and expanded Brave Dreams MRI analysis give a substantive steelman. Reproducibility/specificity and clinical sham trials contradict the broad chain; ideal sustained target correction was incomplete and positive MRI lacks prospective clinical confirmation.

The tournament does not alter the nominal level. Compatible pathways and flexible alternatives are not automatically proved by explaining observations.

FULL REVIEW

Registered claim and scope

Correcting chronic cerebrospinal venous insufficiency with venoplasty improves multiple-sclerosis disability and disease activity.

Primary SC3 is the registered clinical policy/benefit claim. Etiologic mechanisms and separately stated harms are reported at their own scope; proof of harm does not itself assign the nominal benefit level.

Selection: position 22 in this three-case user-selected harm-related batch, registered on 2026-10-12; this is not a measured popularity ranking. Registered claim assessed against original sources. Any carried-forward edition and prior visibility are recorded in the change record; no independent blinded calibration is claimed.

Evidence and causal interpretation

Rubric fit: MS is an inflammatory demyelinating disease, not a canonical protein-aggregation tauopathy. Rubric01 is used for disease progression and clinical intervention response; rubric05 supplies immune context. Literal genetic/mediator criteria are preserved as quoted criteria, while a direct human vascular intervention and objective mechanical injury require the explicit per-subclaim adaptations below. A positive MRI finding is not clinical disability efficacy; proven local procedural injury does not prove MS causation.

The original clinical story included actual pressure reduction and early RRMS response in open-label treatment, with high jugular restenosis and limited progressive-disease response. Smaller delayed/wait-list and observational reports offer selected QOL/functional positives and null objective readouts. These comparisons remain vulnerable to selection, expectation, natural fluctuation and changed therapy; observed deterioration after treatment is not automatically treatment-caused. PMID 19958985 PMID 21839654 PMID 31445091 PMID 26891024 PMID 28270250 PMID 23301864.

PREMiSe is a small sham-controlled original. Hemodynamic success occurred in its open phase but was not sustained to the target in randomized phase2. New-lesion/relapse counts trended adversely without statistically significant simple between-arm results; the exploratory covariance analysis is not a definitive causal exacerbation finding. Canadian randomization in 104 participants found no primary QOL or secondary clinical/MRI benefit, while both arms transiently improved. Serious adverse events were reported in 5 of 49 venoplasty and 1 of 55 sham participants; its blinded physician classified all six as unrelated, and an asymptomatic local jugular dissection remains a real procedural event. PMID 24975855 PMID 30266886.

Brave Dreams fell well below intended recruitment and restored flow in only 54% of evaluated treated patients versus 38% sham. Prespecified full-year functional and MRI results did not show benefit; favorable late-period nominal MRI comparisons lost significance after adjustment. The expanded analysis added the progressive subgroup and found a positive lesion-free outcome and stronger favorable-anatomy post hoc MRI signal. This is one parent trial, not replication, and not a positive clinical disability result. The 2020 corrigendum expressly changed secondary to post hoc terminology. PMID 29150995 PMID 31735108.

Initial blinded ultrasound positives, the Sicilian case-control association and a later M-mode positive original prevent the false statement that every diagnostic study was negative. Nonetheless CoSMo, blind-verified and Houston originals failed to establish a reproducible MS-specific composite. Canadian catheter venography found narrowing frequently in cases, unaffected siblings and unrelated controls; MRI companion agreement was poor. Hydration/repeat scanning and trained-reader comparisons expose different reliability questions. Shared-clip reader agreement is not independently acquired physiological reproducibility. PMID 19060024 PMID 24243930 PMID 22870210 PMID 24014572 PMID 23418501 PMID 23418024 PMID 24119384 PMID 27887935 PMID 24175155 PMID 28721810.

Human CSF/perfusion, SWI iron and vessel-visibility associations are credible physiological observations with nonunique causes. Early CIS/pediatric disease can occur without detected CCSVI; venographic narrowing often lacks meaningful pressure gradients. Rat chronic ligation gives iron and gliosis but not inflammation, demyelination, axonal loss or weakness. These results challenge the proposed sufficient/necessary MS chain within tested contexts, while preserving real vascular tissue effects. PMID 20018140 PMID 22915599 PMID 20351672 PMID 22011402 PMID 21280079 PMID 22513520 PMID 23828872 PMID 28430292.

Safety is a separate causal question. Objectively localized thrombosis after balloon treatment and thrombosed/migrated stents, vessel rupture/dissection and balloon retrieval establish possible iatrogenic harm. Supervised balloon-only trials had low local event burden and no attributed serious procedural events. Selected referrals and the 462-person Italian series cannot make every later pneumonia, seizure or MI death procedural; systemic events require adjudication. Exact abstract denominators inconsistent in one large series are not promoted as verified. The inaccessible harm corrigendum limits corrected numerical confidence. PMID 21803799 PMID 21107001 PMID 21679067 PMID 21856578 PMID 23249660 PMID 23948669 PMID 23380649 PMID 30266886.

HYPOTHESIS STATE EVALUATION FRAMEWORK (HSEF v5.3)

Subclaim matrix and aggregation

Preregistered aggregation: primary-subclaim. Preregistered primary-SC3 aggregation returns Β: meaningful flow/MRI evidence is retained, but clinical benefit is not demonstrated and sham improvement supplies a more parsimonious explanation for uncontrolled subjective response. A single Step11 downgrade from the Γ mechanistic/proxy starting point is explicit. Weakest-link aggregation would return Α because SC1 universal reproducibility/specificity fails; procedural injury Ε is separate and cannot determine a benefit score. Sensitivities: weakest-link Α; primary-subclaim Β; scope-matched Β.

Decisive-perturbation inventory and causal tally

[1] PREMiSe phase2 randomized 19 patients to venoplasty or sham; no clinical benefit and no sustained prespecified hemodynamic success in the randomized phase. Lesion and relapse counts trended adversely without significant between-arm differences. Small pilot, incomplete target engagement and exploratory analyses do not establish causal disease exacerbation. Linked erratum details were not supplied in PubMed and remain unchecked.

[2] Canadian sham-controlled trial randomized 104 participants; primary MSQOL54 change and secondary clinical/MRI outcomes did not improve with venoplasty. Both arms had transient subjective improvement. One asymptomatic jugular dissection occurred after venoplasty. Only 60% planned power for the primary effect size and 48-week follow-up limit small/late effects. Serious adverse events occurred in 5 of 49 venoplasty and 1 of 55 sham participants; the blinded physician judged all six unrelated to the procedure, so they are not counted as procedural injury, but the arm imbalance is recorded.

[3] Brave Dreams randomized 115 RRMS patients; functional improvement and full-year MRI outcomes were not significantly better after angioplasty. Restored flow was observed in 38/71 treated and 14/37 sham participants; no procedure-attributed serious event occurred. Underrecruitment and incomplete engagement constrain an ideal-flow mechanism test. Favorable late MRI comparisons lost significance after multiplicity adjustment; clinical and MRI outcomes remain distinct.

[4] Expanded Brave Dreams analysis added 15 progressive patients; treated participants were more often free of new MRI lesions, RR 1.42, 95% CI 1.00–2.01, p = 0.032. Favorable venographic anatomy showed stronger post hoc MRI associations. Same randomized parent as 29150995, no independent clinical efficacy replication. Correction 31896294 explicitly labels classification post hoc; discordant classifications were excluded. MRI movement does not establish disability benefit.

[21] A patient developed jugular thrombosis after balloon venoplasty without a stent despite anticoagulation, requiring surgical thrombectomy. Objective local mechanical complication supports a can-cause claim, not the frequency of injury or a causal MS-worsening estimate.

[22] Procedural series documented two thrombotic stent occlusions and surgical femoral venotomy to retrieve an angioplasty balloon. Mixed balloon/stent exposure and short observation do not yield one universal liberation-therapy risk; mechanical failures can be causally linked within their settings.

[26] Foundational study found abnormal Doppler patterns in all 65 MS patients and none of selected controls, with venographic stenoses in screen-positive patients. Ultrasound was blinded, but invasive venography knew diagnosis and used ultrasound-positive selection plus controls undergoing venography for other illnesses; this is association, not temporal or causal proof.

[30] CoSMo multicenter blinded local/central reading found similar low CCSVI prevalence in MS, other neurodegenerative diseases and healthy controls, with low positive agreement. Diagnostic negative result concerns specified criteria and adjudication, not every vascular abnormality. Rare positives and operator disagreement bound sensitivity claims.

[36] Blind-verified study found CCSVI in 30.9% of MS patients and 33.8% of controls; experienced, specifically trained operators showed variable estimates. Blinding was successful in cases but imperfect in controls; single-study null does not show no vascular pathology, while training alone does not restore MS specificity.

[41] Blinded M-mode-enhanced Doppler study found CCSVI in 59.8% of 112 MS patients and none of 67 controls. Important positive original remains contrary to other blinded studies; modality/protocol dependence and no prospective causal manipulation block universal specificity.

[67] Chronic jugular ligation in rats produced iron deposition and reactive gliosis, but no demyelination, axonal loss, inflammation or neurological weakness after eight months. Positive vascular tissue effects remain real. Severe artificial ligation and collateral anatomy differ from human CCSVI; this is a scoped sufficiency challenge, not proof that all vascular roles in MS are absent.

[68] Blinded Canadian catheter-venography study found greater-than-50% narrowing similarly common in MS, unaffected siblings and unrelated controls; ultrasound poorly identified such narrowing. Anatomical narrowing is not validated pathological obstruction; incomplete invasive observations and fixed definitions bound generalization.

Tally: 3 positive qualifying study units across scoped subclaims; 32 screened discriminating contrast units. These are not independent causal lines or proof of full-claim necessity/sufficiency. Null and negative contrasts are discriminators, not positive threshold crossings. Reports and replications are not independent causal lines. Reports sharing participants, models or instruments are not independent causal lines. Pivotal nulls do not earn positive threshold crossings.

Cap audit, precedence and Β/Γ/Δ boundary

Positive physical dilation/flow/pressure and MRI results retain their tested scope. The universal biomarker-only cap limits the inference to disability benefit. Native mechanical procedural injury is scored separately with an explicit adapted field-valid criterion, not recapped as pure association merely because randomized exposure to a complication is unethical. No negative RCT is counted as a positive clinical threshold crossing.

Universal six-cap audit: All six universal caps were considered: cell-only inference, unperturbed association, ectopic expression, biomarker-only intervention, forced transfer/seeding, and inherited-to-sporadic scope transfer. Each binds its offered inference; complementary same-scope causal classes are assessed together rather than re-capped in isolation.

Gamma hard-rule audit: Venous pressure/flow restoration is target engagement rather than a positive disability endpoint. MRI lesions, iron deposition and gliosis do not substitute for clinical benefit or inflammatory demyelination. The rubric aggregation/seeding/organoid hard rules do not literally apply to venoplasty; the pertinent boundary is positive disease-relevant intervention and specific vascular causation.

SC1 field-valid definition: “ - Endogenous genetic deletion, suppression, or degron depletion of the proposed mediator in vivo - Selective pathway inhibition that changes onset/progression while preserving broader viability - Vagotomy-type natural experiment, only if confounding is rigorously controlled AND effect is disease-initiation relevant rather than merely associated” Positive full-scope result: no. Initial associations reach at most Β, and the literal specificity/reproducibility claim is downgraded once to Α because blinded multicenter and sibling-controlled originals show common narrowing without MS specificity and unstable/operator-dependent composite diagnosis. Positive M-mode and trained-reader originals are retained; the result is about the universal composite, not the existence of real venous lesions.

SC2 field-valid definition: “ - Endogenous genetic deletion, suppression, or degron depletion of the proposed mediator in vivo - Selective pathway inhibition that changes onset/progression while preserving broader viability - Vagotomy-type natural experiment, only if confounding is rigorously controlled AND effect is disease-initiation relevant rather than merely associated” Positive full-scope result: no. Iron/gliosis after rat ligation and human CSF/perfusion associations support a mechanistic starting ceiling Γ. Early MS/CIS without confirmed CCSVI and ligation without inflammatory demyelination challenge the necessary/sufficient initiating chain: one scoped causal-pattern downgrade gives Β. Artificial exposure, limited timing and detection prevent a universal statement that vascular biology cannot affect MS.

SC3 field-valid definition: “ - Endogenous genetic deletion, suppression, or degron depletion of the proposed mediator in vivo - Selective pathway inhibition that changes onset/progression while preserving broader viability - Vagotomy-type natural experiment, only if confounding is rigorously controlled AND effect is disease-initiation relevant rather than merely associated” Positive full-scope result: no. Flow/pressure responses and the positive expanded Brave Dreams MRI finding justify considering Γ. The same trial did not show clinical functional benefit, and independent Canadian/PREMiSe sham comparisons failed to confirm the uncontrolled subjective response. One parsimonious-alternative falsification downgrade (expectation/regression and nonspecific response observed in sham) yields Β for clinical benefit. Incomplete target engagement means a complete mechanism-blocking falsification is not claimed; the positive MRI finding remains a research lead.

SC4 field-valid definition: “ - Endogenous genetic deletion, suppression, or degron depletion of the proposed mediator in vivo - Selective pathway inhibition that changes onset/progression while preserving broader viability - Vagotomy-type natural experiment, only if confounding is rigorously controlled AND effect is disease-initiation relevant rather than merely associated” Positive full-scope result: yes. Objective local thrombosis after balloon treatment, thrombosed/migrated stents and procedural vessel/device injury demonstrate that this intervention can cause harm in defined clinical settings. Ε preserves mapped technique/operator and serious-event boundaries; uncontrolled delayed systemic events and selected referrals cannot supply a universal causal incidence. Clinical balloon-only RCTs reported few local complications and no procedure-related serious adverse events.

SC1 applied rubric adaptation (distinct from the unchanged literal criterion): Reproducible blinded vascular assessment and MS/sibling/healthy disease specificity substitute for neuropathological exposure association. This diagnostic subclaim is not itself a disease-causal perturbation; trained reader agreement does not satisfy an endogenous mediator criterion.

SC2 applied rubric adaptation (distinct from the unchanged literal criterion): Disease-relevant human temporal dependency, or experimentally imposed venous obstruction yielding inflammatory demyelination and progression with matched controls, would support a causal vascular contribution. Rodent iron/gliosis alone is a proxy; no selective human initiation experiment is asserted.

SC3 applied rubric adaptation (distinct from the unchanged literal criterion): For the registered clinical claim, sham-controlled human balloon venoplasty with verified sustained flow correction and a clinically meaningful disability/relapse endpoint is the field-valid therapeutic equivalent explicitly allowed in the rubric upper-ladder section. Randomization alone does not qualify a null as positive causal support; incomplete flow correction limits inference to an ideal fully engaged mechanism.

SC4 applied rubric adaptation (distinct from the unchanged literal criterion): The criterion is adapted to objective native human procedure-related vascular injury, such as new local jugular thrombosis, vessel rupture/dissection, stent migration or device retrieval, with anatomy and temporal/mechanical linkage. It is not the literal MS disease-onset perturbation criterion. Ε reflects demonstrated injury in bounded balloon/stent and operator contexts, with lower serious-event occurrence in supervised balloon-only trials; no universal frequency, fatality or MS-exacerbation claim.

SC1 literal Γ hard rule: “In vitro aggregation alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC1 literal Γ hard rule: “In vitro seeding alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC1 literal Γ hard rule: “Droplet aging in vitro” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC1 literal Γ hard rule: “Organoid toxicity without organismal follow-through” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC1 literal Γ hard rule: “Exogenous seeding models alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC2 literal Γ hard rule: “In vitro aggregation alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC2 literal Γ hard rule: “In vitro seeding alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC2 literal Γ hard rule: “Droplet aging in vitro” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC2 literal Γ hard rule: “Organoid toxicity without organismal follow-through” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC2 literal Γ hard rule: “Exogenous seeding models alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC3 literal Γ hard rule: “In vitro aggregation alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC3 literal Γ hard rule: “In vitro seeding alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC3 literal Γ hard rule: “Droplet aging in vitro” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC3 literal Γ hard rule: “Organoid toxicity without organismal follow-through” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC3 literal Γ hard rule: “Exogenous seeding models alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC4 literal Γ hard rule: “In vitro aggregation alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC4 literal Γ hard rule: “In vitro seeding alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC4 literal Γ hard rule: “Droplet aging in vitro” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC4 literal Γ hard rule: “Organoid toxicity without organismal follow-through” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC4 literal Γ hard rule: “Exogenous seeding models alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

Upward threshold ladder

SC1 Δ: “Requires at least one genuine causal perturbation in a disease-relevant in vivo system, or equivalent human natural experiment that materially supports the mechanism.” Satisfied: no. An independently acquired, prospectively fixed imaging/pressure classifier must replicate across blinded centers and distinguish MS from siblings/healthy/other-neurological controls, at stable physiological conditions and without case-dependent verification.

SC2 Δ: “Requires at least one genuine causal perturbation in a disease-relevant in vivo system, or equivalent human natural experiment that materially supports the mechanism.” Satisfied: no. Show early MS-relevant inflammation/demyelination follows independently verified venous obstruction, and selective correction alters the clinical trajectory, with collateral/pressure, immune and sham controls and a prospective scope.

SC3 Δ: “Requires at least one genuine causal perturbation in a disease-relevant in vivo system, or equivalent human natural experiment that materially supports the mechanism.” Satisfied: no. A prospectively registered blinded comparison must show meaningful clinical benefit with confirmed sustained flow correction, stable usual therapy, adequate power, and intention-to-treat results; prespecified anatomy may be tested but post hoc responders cannot rescue the broad claim.

SC4 Δ: “Requires at least one genuine causal perturbation in a disease-relevant in vivo system, or equivalent human natural experiment that materially supports the mechanism.” Satisfied: yes.

SC4 Ε: “Requires causal support in a defined context, but with clear restriction by subtype, disease stage, model, or tissue.

Use Ε when there is a real causal contribution, but generalization to the entire disease class fails.” Satisfied: yes.

SC4 Ζ: “Requires: - Multiple independent causal lines in vivo - Replication across at least two relevant systems - Narrowing of major alternative models” Satisfied: no. Further upper support requires prospectively ascertained objective causal complications with complete procedure denominators, harmonized attribution and longer surveillance across balloon/stent/operator settings; delayed systemic events require alternative-cause adjudication.

Upper ladder: Human sham-controlled therapeutic perturbations are feasible and present. Their clinical nulls do not support upward positive thresholds. Independent genetic instruments, robust early natural experiments or a selective sustained-target human clinical benefit were not verified. Local procedural injury has causal mechanical evidence, but broad risk frequency and universal clinical harm are not established by selected case reports.

Independence: Count parent trials and recruitment cohorts, not publications. Brave Dreams reports share randomized participants; Canadian sibling MRI/venography are one diagnostic study; PREMiSe imaging/trial are one unit; Italian clinical and harm reports share 462 patients. Initial 65-case and 16-case reports and CTEVD imaging/clinical resources are grouped conservatively where overlap is plausible. Case referral selection does not become incidence through replication.

Clinical sham interventions [1, 2, 3]: Independent trials reduce uncontrolled expectation, but incomplete engagement, low power and selected recruitment remain; 31735108 is the same Brave Dreams parent.

Diagnostic specificity and physiological state [68, 36, 57]: Sibling controls, blind verification and hydration manipulation have distinct errors; fixed ultrasound criteria and shared operator assumptions still overlap.

Objective procedural injury [21, 22, 16]: Local thrombosis/device injury across settings reduces delayed-systemic-event attribution error; mixed procedures and shared clinical services constrain pooled rates.

Falsification and pitfalls

SC1: Alternative models explain the same findings more parsimoniously. Common narrowing in siblings/healthy controls plus criterion/operator/state dependence contradict universal MS specificity. Apply one downgrade from the initial Β association ceiling to Α, retaining contrary positive originals. Additional downgrade: True.

SC2: Pathology still initiates in its absence. Early CIS/MS without confirmed CCSVI challenges necessary initiation; ligation without demyelination adds a related sufficiency boundary. Apply one scoped downgrade Γ to Β, not a separate double penalty for each report. Detection and model-exposure limitations are explicit. Additional downgrade: True.

SC3: Alternative models explain the same findings more parsimoniously. Sham reproduces transient subjective gains and clinical randomized endpoints do not separate, explaining uncontrolled benefits without intervention-specific MS efficacy. Apply one downgrade Γ to Β. Repeated trial nulls are not multiple patterns; complete mechanism blockade is not claimed with incomplete target engagement. Additional downgrade: True.

SC4: No triggered falsification of the bounded can-cause mechanical injury claim. Low serious-event occurrence in supervised balloon protocols limits rate/generalization; it does not contradict objectively documented thrombosis/device injury elsewhere. Additional downgrade: False.

Flow/MRI substituted for clinical causality. Target engagement and lesion-free MRI findings cannot establish disability benefit.

Same-trial reanalysis counted as independent replication. Brave Dreams expanded population and anatomical post hoc analysis share the parent trial.

Failure to engage the target treated as complete mechanism blockade. PREMiSe and Brave Dreams incomplete flow correction limit causal null interpretation.

All events after treatment assigned to the procedure. Mechanical local injury differs from delayed systemic illness; RCT attribution and referral selection matter.

Successful readers equated with independent physiological reproducibility. Shared-clip central/local agreement does not settle independent acquisition or disease specificity.

Adversarial steelman: above, then below

One rung above, Γ: pressure and flow correction, original RRMS improvements and positive expanded Brave Dreams MRI effects support a biologically credible intervention. Only 54% of treated participants had restored flow in Brave Dreams, PREMiSe missed randomized hemodynamic success, and trials were underpowered for some small effects. Those are substantial reasons to avoid claiming an ideal fully engaged mechanism is disproven. The blocker is the registered clinical-benefit claim: independent blinded clinical results fail to separate from sham and transient improvement occurs in sham, triggering one parsimonious-alternative downgrade.

One rung below, Α: poor specificity and repeated clinical nulls could make the whole chain conceptual or artifactual. However, actual target responses, positive blinded diagnostic originals and a positive expanded MRI endpoint mean the benefit hypothesis is not devoid of mechanistic empirical content. Incomplete engagement prevents counting every null as complete mechanism ablation. No second independent falsification pattern is imposed merely by repeating the same clinical comparator failure.

Retain Β for the registered benefit scope, Α for the universal diagnostic claim and Ε for bounded objective procedural injury. The positive MRI reanalysis and genuine vascular effects remain visible; no subgroup redefinition or procedural-harm finding rescues/condemns the benefit score by substitution.

Final score, causal direction and M/S/D

Preregistered primary-SC3 aggregation returns Β: meaningful flow/MRI evidence is retained, but clinical benefit is not demonstrated and sham improvement supplies a more parsimonious explanation for uncontrolled subjective response. A single Step11 downgrade from the Γ mechanistic/proxy starting point is explicit. Weakest-link aggregation would return Α because SC1 universal reproducibility/specificity fails; procedural injury Ε is separate and cannot determine a benefit score.

For CCSVI as a driver of MS, no demonstrated causal dependency in either direction is established by this corpus, so step2 returns epiphenomenon as the framework category for the proposed MS-driver relationship. This label does not mean veins are physiologically inert. The role procedure separately demonstrates a causal initiating role for some local iatrogenic injuries; fitting that safety mechanism into the nominal MS-role label would conflate two claims.

Momentum: Little new work. The bounded registered searches through 12 October 2026 retrieved the completed PREMiSe, Canadian, Brave Dreams and wait-list trials plus the expanded 2019-online/2020-issue MRI report, without a verified newer decisive sham clinical result in this selected corpus. This is a search-bounded trajectory judgment, not proof that randomized work ceased globally or no trial is ongoing.

Stability: Stable. No named verified pending result determining the clinical-benefit level was identified. Prospective sustained-target anatomy-stratified clinical replication could raise it, but the proposed experiment is not a verified underway program.

Divergence: Contested. No manufactured field consensus or arithmetic gap. These dimensions do not change level or confidence.

PROPOSED DECISIVE EXPERIMENTS

If a scientifically and ethically justified study is contemplated, prospectively fix anatomical/pressure entry criteria and MS stage, verify sustained flow correction, randomize balloon venoplasty versus convincing sham with stable usual therapy and adequate clinical power, and test prespecified functional/relapse outcomes alongside MRI without conditioning on post-treatment responders.

Readout: Sustained blinded target flow/pressure, disability function, relapses, MRI lesions and separately attributed vascular/device complications. Controls: Sham blinding assessment, stable disease-modifying therapy, independent venographic/flow adjudication, intention-to-treat analysis, prespecified anatomy interaction, collateral physiology and procedure-denominator safety follow-up. Supporting: Meaningful clinical advantage over sham with sustained engagement, prospective anatomical effect modification and independent replication. Falsifying: No clinical separation despite reliable target correction, or only exploratory MRI/subjective changes without functional benefit.

KNOWLEDGE GAPS

Validate a stable pathological-obstruction definition using independent blinded acquisition, pressure/flow and sibling/healthy controls.

Separate procedural success, sustained target engagement and clinical mediation; low engagement is a limitation rather than a responder-defined rescue.

Prospectively test the favorable-anatomy MRI lead against clinical outcomes and multiplicity control in an independent cohort.

Clarify stage, collateral and inflammatory mechanisms without generalizing rat iron/gliosis to human demyelination.

Establish objective long-term complication denominators by balloon/stent and operator setting with independent causal adjudication.

Audit supplements and correction bodies unavailable in this bounded source examination; do not convert access failures to negative findings.

REVIEWER NOTES

69 selected relevant primary reports were examined at bounded original abstract/status depth; eight also have selected original Methods/Results paragraph receipts. No complete-paper or supplement audit is claimed. The study count includes follow-up and diagnostic companion reports whose parent units are identified. PubMed RCT indexing was overridden where the actual original design is observational. Brave Dreams correction details were examined publicly and attached; the harm corrigendum body was blocked (HTTP 403) and PREMiSe linked erratum lacks identifier/details in the fetched record. Scite quota was exhausted earlier; no repeat call, fresh tally or incoming-context audit. Actual Consensus browser output is checked against originals, and provider asserted PDF access is not reviewer full-text access. No independent blinded grading or peer review is claimed. Coordinating source/claim checks and registered-scope adjudication are recorded in COORDINATOR_ADJUDICATION.json. This is not an independent blinded regrade. HSEF letters measure support for the exact positive claim; negative clinical findings and documented harms are explained separately. Divergence is not a probability or a claim of evenly balanced medical evidence.

Search leads, reviews, protocols and correction notices do not pad the primary count. Downloaded XML does not earn examination credit. Linked notices remain attached; unexamined correction details limit inference. This is a coordinator source/claim consistency assessment, not independent blinded calibration.

Consensus and original-source reconciliation

Consensus relied on clinical summaries rather than the requested original and described paradoxical exacerbation too decisively. The bounded original abstract reports nonsignificant between-group new-lesion and relapse trends in a 19-participant randomized phase, plus an exploratory covariance association. Its randomized target-engagement criterion was not achieved. The original body was unavailable this run: abstract-only attribution is explicit, and neither ideal mechanism ablation nor established worsening is claimed. Original PMID24975855.

Consensus omitted this requested original and substituted a pooled review. Original Methods/Results were examined: 104 randomized participants, primary MSQOL54 change, secondary disability/relapse/MRI, independent assignment and blinded assessors. Both groups transiently improved; no clinical benefit separated. The planned primary-effect power was only 60%, so small or delayed effects remain bounded rather than excluded. Original PMID30266886.

Consensus correctly retained 115 RRMS participants and 38/71 restored-flow treated patients. Original Methods show co-primary functional and MRI endpoints, early trial closure at 115 versus amended target of 300, intention-to-treat and multiplicity adjustment. Original Results include restored flow in 14/37 sham participants and favorable late nominal MRI comparisons that lost adjusted significance. These details limit a complete-blockade interpretation while preserving the negative clinical finding. Original PMID29150995.

Consensus correctly identified the expanded 130-patient analysis and positive lesion-free result, but the evidence is one Brave Dreams parent, not clinical replication. Examined original Methods/Results show added progressive patients, post hoc anatomy grading, exclusion of discordant classifications and positive MRI comparisons. The examined 2020 correction explicitly changes secondary-analysis terminology to post hoc. No numerical-effect change is stated in that correction. Prospective independent clinical validation remains the relevant gap. Original PMID31735108.

Consensus used initial diagnostic papers and an early CIS original, omitting the key sibling-controlled venography study. Its bounded original abstract shows greater-than-50% narrowing similarly common in MS, unaffected siblings and unrelated controls; ultrasound poorly identified catheter narrowing. The companion MRV report is grouped with this parent rather than counted as independent population replication. Anatomical narrowing alone does not establish pathological obstruction. Original PMID24119384.

Consensus summarized diagnostic reproducibility mainly negatively. The examined original Methods/Results retain substantial agreement between expert local and central readers, particularly for selected criteria. Shared acquired recordings differ from independently reproduced acquisition/physiology; positive reader agreement therefore survives alongside the cross-center specificity challenge. Original PMID28721810.

Consensus appropriately found the jugular-thrombosis case. Its bounded original abstract supports local thrombosis after balloon venoplasty without stenting despite anticoagulation, requiring surgery. This shows possible mechanical injury; it supplies neither a general incidence nor proof that every postprocedure clinical deterioration was caused by treatment. Original PMID21803799.

Consensus listed fatal pulmonary-embolus hazards among catastrophically attributed stent outcomes. The examined original case reports imaging-confirmed displacement/thrombosis and discusses a potential future fatal embolic event; no fatal pulmonary embolus was observed in this case. Device harm remains real, but speculative hazards are distinguished from observed fatalities. Original PMID23249660.

Consensus safety wording overgeneralized causal systemic harms. This original reports serious events at variable post-treatment intervals in the same 462-person parent as the clinical report; seven jugular thromboses are mechanically plausible, while a myocardial-infarction death ten weeks later and other systemic events are not all established procedure-caused. The linked harm correction body was blocked (HTTP 403), so corrected numerical details remain unverified. Canadian original-body adjudication separately found its six serious events unrelated, while retaining one local jugular dissection. Original PMID23380649.

Consensus claimed randomized tests ceased entirely and a complete hiatus through late 2026 based on 2019/2020 sources. The selected original wait-list trial provides a completed objective-null/subjective-mixed milestone, not proof of global absence of later trials. Our search-bounded momentum judgment names completed original programs and explicitly makes no universal current registry or regulatory-status claim. Original PMID31445091.

Consensus was used to identify literature and cross-check specific claims about design, endpoints, scope and research gaps. Those aspects were checked against original primary abstracts/status records and selected original Methods/Results passages. Consensus output was not treated as original full text. Provider search omissions are not evidence that a study does not exist. Source access and examination receipts are retained. Scite use or monthly unavailability is recorded per case; provider citation counts do not change causal grades.

Research timeline and gaps: CCSVI and Liberation Therapy for Multiple Sclerosis

Selected publication milestones, not an exhaustive history or discovery priority claim.

2009 — Foundational case-control association proposes MS-specific venous abnormalities; PubMed issue year2009 follows online2008. Original PMID19060024.

2009 — Open-label venoplasty reports pressure and selected RRMS changes, with high jugular restenosis. Original PMID19958985.

2011 — Objective balloon-only jugular thrombosis documents a possible procedural complication. Original PMID21803799.

2014 — Blinded sibling/control venography challenges disease-specific pathological narrowing; issue2014 follows online2013. Original PMID24119384.

2014 — PREMiSe randomized pilot tests sham comparison and target engagement without demonstrated clinical efficacy. Original PMID24975855.

2018 — Brave Dreams finds no clinical functional benefit with incomplete flow correction; online2017, issue2018. Original PMID29150995.

2018 — Independent Canadian sham trial finds no primary QOL or secondary clinical/MRI benefit. Original PMID30266886.

2020 — Expanded same-trial MRI analysis provides a positive lesion-free lead; online2019, issue2020. Original PMID31735108.

Research gaps

Validate a stable pathological-obstruction definition using independent blinded acquisition, pressure/flow and sibling/healthy controls.

Separate procedural success, sustained target engagement and clinical mediation; low engagement is a limitation rather than a responder-defined rescue.

Prospectively test the favorable-anatomy MRI lead against clinical outcomes and multiplicity control in an independent cohort.

Clarify stage, collateral and inflammatory mechanisms without generalizing rat iron/gliosis to human demyelination.

Establish objective long-term complication denominators by balloon/stent and operator setting with independent causal adjudication.

Audit supplements and correction bodies unavailable in this bounded source examination; do not convert access failures to negative findings.

Boundary experiment

If a scientifically and ethically justified study is contemplated, prospectively fix anatomical/pressure entry criteria and MS stage, verify sustained flow correction, randomize balloon venoplasty versus convincing sham with stable usual therapy and adequate clinical power, and test prespecified functional/relapse outcomes alongside MRI without conditioning on post-treatment responders.

ADVERSARIAL REVIEW AND APPROVAL

Authoring model: Sol 6.1. Adversarial reviewer: Claude Opus 5.5 (Anthropic). Date: 2026-10-14.

Scope of checks. All 69 REFERENCES PMIDs plus the two in-text correction PMIDs (28072565, 31896294) were resolved against PubMed and matched on title, first author, journal and year: 71/71 resolved, no wrong identifiers, no retraction or expression-of-concern flags. Sixteen load-bearing claims were spot-checked against source abstracts (PREMiSe 24975855; Canadian sham trial 30266886; Brave Dreams 29150995; expanded Brave Dreams 31735108; Zamboni open-label 19958985; Zamboni pilot 21839654; wait-list 31445091; Italian 462-case series 23354606 and its adverse-event report 23380649; Ludyga safety series 21107001; Petrov safety series 21679067; Lupattelli 23948669; CoSMo 24014572; Traboulsee sibling venography 24119384; Leone blind-verified 23418501; Tromba M-mode 24243930; rat ligation 28430292, checked against the publisher abstract because the PubMed record carries none). Scoring logic was re-derived from references/hsef-framework.md and SKILL.md Steps 2-3 and 8: cap order, the pre-registered primary-subclaim rule, the reported alternatives, the Beta/Gamma/Delta boundary, the independence basis and the role-derivation step were each re-checked.

Findings

Rejected findings (checked, no change)

• "Best-supported rival" names the correct model. The score card marks the rank-1 model is_nominal: false and the nominal model at its own lower rank; the AT A GLANCE prose names the rank-1 rival, so the renderer bug reported elsewhere in this round did not fire here.
• No false-approval or foreign-provenance clause. This case is not one of the 9 October revised editions, carries no "earlier adversarial approval" sentence, and its Selection and methods provenance statements were each checked against the package and apply to this case. REVIEWER NOTES and the Consensus section do not contradict each other.
• Headline letter Beta and the primary-subclaim rule. Re-derived independently. hypothesis-index.md has no CCSVI entry, so the rule was the reviewer's to choose; it is declared before scoring, the primary subclaim (SC3) is named, and the two alternatives are reported with the correct values: weakest-link Alpha (SC1 is the lowest) and scope-matched Beta (SC3 is the only subclaim whose scope matches the registered clinical-benefit claim). The Epsilon on SC4 is scope-restricted to procedural injury and correctly does not set the headline.
• Causal role epiphenomenon. Step 1 (downstream consequence) was considered: MS onset without detectable CCSVI (PMID 21280079, 22513520) and the age and disease-duration dependence (PMID 23406210, 23418501) are compatible with a consequence reading, but PMID 23301144 found no relation between MS duration and venous-lesion severity, so no causal dependency is demonstrated in either direction and step 2 governs.
• Momentum "Little new work". The framework requires a named artifact; the review names the completed PREMiSe, Canadian, Brave Dreams and wait-list programmes and states the search bound. It is not the "Decisive work underway" boilerplate.
• Divergence "Contested". Permitted without an arithmetic gap where no single implied level applies; the review states that explicitly.
• Collective-author rendering. REFERENCE 21 renders the consortium correctly ("Imperial College CCSVI Investigation Group, Thapar A, Lane TR et al."), matching the PubMed record for PMID 21803799, whose author list begins with an authorless collective entry. No other reference has a collective first author.
• Citation years. PMID 21839654 (2012 issue, 2011 e-pub), 31445091 (2020/2019), 31735108 (2020/2019), 22088659 (2012/2011), 19060024 (2009/2008), 24243930 (2015 issue, 2013 e-pub) and 24531803 (2015/2014) all print the issue year; per the standing convention these are not errors.
• Compact numeric tokens ("phase2", "rubric01", "Step11", "MSQOL54", "online2019") are house style throughout this document and were left alone.
• PMID 28430292 (rat jugular ligation). The PubMed record carries no abstract, so the detailed attribution could not be checked at the review's declared access level. The publisher abstract confirms every element: eight-month follow-up, increased white-matter iron, increased astrocyte size and number with raised GFAP immunoreactivity, and no demyelination, inflammation, axonopathy, weakness or paralysis. Content verified; no change.

Residual limitations

The corrigendum body for PMID 23380649 remains inaccessible, so the corrected adverse-event numerators for the 462-patient Italian series are still unverified; the review already says so. Target-engagement percentages, power calculations and the amended Brave Dreams recruitment target rest on partial-body passages that this adversarial pass did not independently re-retrieve. The harm corpus is built from case reports and uncontrolled series, so it supports a can-cause claim and not an incidence, exactly as the review states.

Approval: Following adversarial review and the corrections listed above, the revised document is approved. — Claude Opus 5.5 (Anthropic), 2026-10-14.

REFERENCES

1. Siddiqui AH, Zivadinov R, Benedict RH et al. Prospective randomized trial of venous angioplasty in MS (PREMiSe). Neurology. 2014. PMID 24975855. DOI: 10.1212/WNL.0000000000000638. Access: abstract_metadata. Study: PREMiSe-NCT01450072.

2. Traboulsee AL, Machan L, Girard JM et al. Safety and efficacy of venoplasty in MS: A randomized, double-blind, sham-controlled phase II trial. Neurology. 2018. PMID 30266886. DOI: 10.1212/WNL.0000000000006423. Access: full_text_partial. Study: PMID30266886.

3. Zamboni P, Tesio L, Galimberti S et al. Efficacy and Safety of Extracranial Vein Angioplasty in Multiple Sclerosis: A Randomized Clinical Trial. JAMA neurology. 2018. PMID 29150995. DOI: 10.1001/jamaneurol.2017.3825. Access: full_text_partial. Study: BraveDreams-NCT01371760.

4. Zamboni P, Galeotti R, Salvi F et al. Effects of Venous Angioplasty on Cerebral Lesions in Multiple Sclerosis: Expanded Analysis of the Brave Dreams Double-Blind, Sham-Controlled Randomized Trial. Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists. 2020. PMID 31735108. DOI: 10.1177/1526602819890110. Access: full_text_partial. Study: BraveDreams-NCT01371760.

5. Zamboni P, Galeotti R, Weinstock-Guttman B et al. Venous angioplasty in patients with multiple sclerosis: results of a pilot study. European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery. 2012. PMID 21839654. DOI: 10.1016/j.ejvs.2011.03.035. Access: abstract_metadata. Study: PMID21839654.

6. Napoli V, Berchiolli R, Carboncini MC et al. Percutaneous Venous Angioplasty in Patients with Multiple Sclerosis and Chronic Cerebrospinal Venous Insufficiency: A Randomized Wait List Control Study. Annals of vascular surgery. 2020. PMID 31445091. DOI: 10.1016/j.avsg.2019.05.018. Access: abstract_metadata. Study: PMID31445091.

7. Zamboni P, Galeotti R, Menegatti E et al. A prospective open-label study of endovascular treatment of chronic cerebrospinal venous insufficiency. Journal of vascular surgery. 2009. PMID 19958985. DOI: 10.1016/j.jvs.2009.07.096. Access: abstract_metadata. Study: FIRST65-possible-overlap.

8. Ghezzi A, Annovazzi P, Cocco E et al. Endovascular treatment of CCSVI in patients with multiple sclerosis: clinical outcome of 462 cases. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2013. PMID 23354606. DOI: 10.1007/s10072-013-1300-5. Access: abstract_metadata. Study: ITALIAN462.

9. Sadovnick AD, Yee IM, Attwell-Pope K et al. Patient-Reported Benefits of Extracranial Venous Therapy: British Columbia CCSVI Registry. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques. 2017. PMID 28270250. DOI: 10.1017/cjn.2017.27. Access: abstract_metadata. Study: PMID28270250.

10. Metz LM, Greenfield J, Marrie RA et al. Medical Tourism for CCSVI Procedures in People with Multiple Sclerosis: An Observational Study. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques. 2016. PMID 26891024. DOI: 10.1017/cjn.2015.350. Access: abstract_metadata. Study: PMID26891024.

11. Alroughani R, Lamdhade S, Thussu A. Endovascular treatment of chronic cerebrospinal venous insufficiency in multiple sclerosis: a retrospective study. The International journal of neuroscience. 2013. PMID 23301864. DOI: 10.3109/00207454.2012.759569. Access: abstract_metadata. Study: PMID23301864.

12. Kostecki J, Zaniewski M, Ziaja K et al. An endovascular treatment of Chronic Cerebro-Spinal Venous Insufficiency in multiple sclerosis patients - 6 month follow-up results. Neuro endocrinology letters. 2011. PMID 21876515. DOI: none in PubMed record. Access: abstract_metadata. Study: PMID21876515.

13. Kipshidze N, Rukhadze I, Archvadze A et al. Endovascular treatment of patients with chronic cerebrospinal venous insufficiency and multiple sclerosis. Georgian medical news. 2011. PMID 22155803. DOI: none in PubMed record. Access: abstract_metadata. Study: PMID22155803.

14. Zagaglia S, Balestrini S, Perticaroli E et al. Percutaneous transluminal angioplasty for chronic cerebrospinal venous insufficiency in multiple sclerosis: dichotomy between subjective and objective outcome scores. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2013. PMID 23660636. DOI: 10.1007/s10072-013-1450-5. Access: abstract_metadata. Study: PMID23660636.

15. Scalise F, Novelli E, Farina M et al. Venous Hemodynamic Insufficiency Severity Score variation after endovascular treatment of chronic cerebrospinal venous insufficiency. Phlebology. 2015. PMID 24531803. DOI: 10.1177/0268355514524193. Access: abstract_metadata. Study: PMID24531803.

16. Petrov I, Grozdinski L, Kaninski G et al. Safety profile of endovascular treatment for chronic cerebrospinal venous insufficiency in patients with multiple sclerosis. Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists. 2011. PMID 21679067. DOI: 10.1583/11-3440.1. Access: abstract_metadata. Study: PMID21679067.

17. Mandato KD, Hegener PF, Siskin GP et al. Safety of endovascular treatment of chronic cerebrospinal venous insufficiency: a report of 240 patients with multiple sclerosis. Journal of vascular and interventional radiology : JVIR. 2012. PMID 22088659. DOI: 10.1016/j.jvir.2011.09.019. Access: abstract_metadata. Study: PMID22088659.

18. Lupattelli T, Bellagamba G, Righi E et al. Feasibility and safety of endovascular treatment for chronic cerebrospinal venous insufficiency in patients with multiple sclerosis. Journal of vascular surgery. 2013. PMID 23948669. DOI: 10.1016/j.jvs.2013.05.108. Access: abstract_metadata. Study: PMID23948669.

19. Ferra H, Behrens G, Tumer Y et al. Endovascular diagnosis and management of chronic cerebrospinal venous insufficiency: retrospective analysis of 30-day morbidity and mortality in 95 consecutive patients. AJR. American journal of roentgenology. 2013. PMID 23701076. DOI: 10.2214/AJR.12.8938. Access: abstract_metadata. Study: PMID23701076.

20. Ghezzi A, Annovazzi P, Amato MP et al. Adverse events after endovascular treatment of chronic cerebro-spinal venous insufficiency (CCSVI) in patients with multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England). 2013. PMID 23380649. DOI: 10.1177/1352458513475491. Access: abstract_metadata. Study: ITALIAN462.

21. Imperial College CCSVI Investigation Group, Thapar A, Lane TR et al. Internal jugular thrombosis post venoplasty for chronic cerebrospinal venous insufficiency. Phlebology. 2011. PMID 21803799. DOI: 10.1258/phleb.2011.011052. Access: abstract_metadata. Study: PMID21803799.

22. Ludyga T, Kazibudzki M, Simka M et al. Endovascular treatment for chronic cerebrospinal venous insufficiency: is the procedure safe? Phlebology. 2010. PMID 21107001. DOI: 10.1258/phleb.2010.010053. Access: abstract_metadata. Study: PMID21107001.

23. Burton JM, Alikhani K, Goyal M et al. Complications in MS patients after CCSVI procedures abroad (Calgary, AB). The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques. 2011. PMID 21856578. DOI: 10.1017/s0317167100054123. Access: abstract_metadata. Study: PMID21856578.

24. Doležal O, Horáková D, Gdovinová Z et al. Serious complication of percutaneous angioplasty with stent implantation in so called "chronic cerebrospinal venous insufficiency" in multiple sclerosis patient. Prague medical report. 2012. PMID 23249660. DOI: 10.14712/23362936.2015.12. Access: abstract_metadata. Study: PMID23249660.

25. Fankhauser GT, Stone WM, Fu R et al. Spiral vein graft for internal jugular bypass in a patient with multiple sclerosis and suspected chronic cerebrospinal venous insufficiency. Annals of vascular surgery. 2013. PMID 23809937. DOI: 10.1016/j.avsg.2012.05.033. Access: abstract_metadata. Study: PMID23809937.

26. Zamboni P, Galeotti R, Menegatti E et al. Chronic cerebrospinal venous insufficiency in patients with multiple sclerosis. Journal of neurology, neurosurgery, and psychiatry. 2009. PMID 19060024. DOI: 10.1136/jnnp.2008.157164. Access: full_text_partial. Study: FIRST65-possible-overlap.

27. Zamboni P, Menegatti E, Weinstock-Guttman B et al. The severity of chronic cerebrospinal venous insufficiency in patients with multiple sclerosis is related to altered cerebrospinal fluid dynamics. Functional neurology. 2009. PMID 20018140. DOI: none in PubMed record. Access: abstract_metadata. Study: RRMS16-HC8-possible-overlap.

28. Bartolomei I, Salvi F, Galeotti R et al. Hemodynamic patterns of chronic cerebrospinal venous insufficiency in multiple sclerosis. Correlation with symptoms at onset and clinical course. International angiology : a journal of the International Union of Angiology. 2010. PMID 20351674. DOI: none in PubMed record. Access: abstract_metadata. Study: FIRST65-possible-overlap.

29. Zivadinov R, Marr K, Cutter G et al. Prevalence, sensitivity, and specificity of chronic cerebrospinal venous insufficiency in MS. Neurology. 2011. PMID 21490322. DOI: 10.1212/WNL.0b013e318212a901. Access: abstract_metadata. Study: CTEVD-RESOURCE-possible-overlap.

30. Comi G, Battaglia MA, Bertolotto A et al. Observational case-control study of the prevalence of chronic cerebrospinal venous insufficiency in multiple sclerosis: results from the CoSMo study. Multiple sclerosis (Houndmills, Basingstoke, England). 2013. PMID 24014572. DOI: 10.1177/1352458513501231. Access: abstract_metadata. Study: PMID24014572.

31. McAuliffe W, Kermode AG. Mystery of chronic cerebrospinal venous insufficiency: identical venographic and ultrasound findings in patients with MS and controls. AJNR. American journal of neuroradiology. 2013. PMID 23370468. DOI: 10.3174/ajnr.A3390. Access: abstract_metadata. Study: PMID23370468.

32. Brod SA, Kramer LA, Cohen AM et al. Chronic cerebrospinal venous insufficiency: masked multimodal imaging assessment. Multiple sclerosis (Houndmills, Basingstoke, England). 2013. PMID 23828872. DOI: 10.1177/1352458513494493. Access: full_text_partial. Study: HOUSTON276.

33. Barreto AD, Brod SA, Bui TT et al. Chronic cerebrospinal venous insufficiency: case-control neurosonography results. Annals of neurology. 2013. PMID 23418024. DOI: 10.1002/ana.23839. Access: full_text_partial. Study: HOUSTON276.

34. Laukontaus SJ, Kagayama T, Lepäntalo M et al. Doppler ultrasound examination of multiple sclerosis patients and control participants: inter-observer agreement and association with disease. European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery. 2013. PMID 23920002. DOI: 10.1016/j.ejvs.2013.07.003. Access: abstract_metadata. Study: PMID23920002.

35. Imperiale D, Melis F, Giaccone C et al. Chronic cerebrospinal venous insufficiency in multiple sclerosis: a sonographer-blinded case-control study. Clinical neurology and neurosurgery. 2013. PMID 23384545. DOI: 10.1016/j.clineuro.2013.01.003. Access: abstract_metadata. Study: PMID23384545.

36. Leone MA, Raymkulova O, Naldi P et al. Chronic cerebrospinal venous insufficiency is not associated with multiple sclerosis and its severity: a blind-verified study. PloS one. 2013. PMID 23418501. DOI: 10.1371/journal.pone.0056031. Access: full_text_partial. Study: PMID23418501.

37. Amato MP, Saia V, Hakiki B et al. No association between chronic cerebrospinal venous insufficiency and pediatric-onset multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England). 2012. PMID 22513520. DOI: 10.1177/1352458512445943. Access: abstract_metadata. Study: PMID22513520.

38. Jurkiewicz E, Kotulska K, Nowak K et al. MR venography in children and adolescents with multiple sclerosis does not show increased prevalence of extracranial veins anomalies. European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society. 2014. PMID 24411179. DOI: 10.1016/j.ejpn.2013.11.013. Access: abstract_metadata. Study: PMID24411179.

39. Baracchini C, Perini P, Causin F et al. Progressive multiple sclerosis is not associated with chronic cerebrospinal venous insufficiency. Neurology. 2011. PMID 21849656. DOI: 10.1212/WNL.0b013e31822c6208. Access: abstract_metadata. Study: PMID21849656.

40. Chambers B, Chambers J, Cameron H et al. Chronic cerebrospinal venous insufficiency is not more prevalent in patients with mild multiple sclerosis: a sonographer-blinded, case-control ultrasound study. Multiple sclerosis (Houndmills, Basingstoke, England). 2013. PMID 22961213. DOI: 10.1177/1352458512459986. Access: abstract_metadata. Study: MILD-CIS-possible-overlap.

41. Tromba L, Blasi S, Vestri A et al. Prevalence of chronic cerebrospinal venous insufficiency in multiple sclerosis: a blinded sonographic evaluation. Phlebology. 2015. PMID 24243930. DOI: 10.1177/0268355513512823. Access: abstract_metadata. Study: PMID24243930.

42. Costello F, Modi J, Lautner D et al. Validity of the diagnostic criteria for chronic cerebrospinal venous insufficiency and association with multiple sclerosis. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 2014. PMID 24890104. DOI: 10.1503/cmaj.131431. Access: abstract_metadata. Study: PMID24890104.

43. Cardaioli G, Di Filippo M, Bianchi A et al. Extracranial Venous Drainage Pattern in Multiple Sclerosis and Healthy Controls: Application of the 2011 Diagnostic Criteria for Chronic Cerebrospinal Venous Insufficiency. European neurology. 2016. PMID 27384420. DOI: 10.1159/000445540. Access: abstract_metadata. Study: PMID27384420.

44. Baracchini C, Perini P, Calabrese M et al. No evidence of chronic cerebrospinal venous insufficiency at multiple sclerosis onset. Annals of neurology. 2011. PMID 21280079. DOI: 10.1002/ana.22228. Access: abstract_metadata. Study: PMID21280079.

45. Centonze D, Floris R, Stefanini M et al. Proposed chronic cerebrospinal venous insufficiency criteria do not predict multiple sclerosis risk or severity. Annals of neurology. 2011. PMID 21786298. DOI: 10.1002/ana.22436. Access: abstract_metadata. Study: PMID21786298.

46. Patti F, Nicoletti A, Leone C et al. Multiple sclerosis and CCSVI: a population-based case control study. PloS one. 2012. PMID 22870210. DOI: 10.1371/journal.pone.0041227. Access: abstract_metadata. Study: PMID22870210.

47. Van den Berg PJ, Visser LH. The fluctuating natural course of CCSVI in MS patients and controls, a prospective follow-up. PloS one. 2013. PMID 24260106. DOI: 10.1371/journal.pone.0078166. Access: abstract_metadata. Study: PMID24260106.

48. Caprio MG, Marr K, Gandhi S et al. Centralized and Local Color Doppler Ultrasound Reading Agreement for Diagnosis of the Chronic Cerebrospinal Venous Insufficiency in Patients with Multiple Sclerosis. Current neurovascular research. 2017. PMID 28721810. DOI: 10.2174/1567202614666170718095203. Access: full_text_partial. Study: PMID28721810.

49. Zivadinov R, Karmon Y, Dolic K et al. Multimodal noninvasive and invasive imaging of extracranial venous abnormalities indicative of CCSVI: results of the PREMiSe pilot study. BMC neurology. 2013. PMID 24139135. DOI: 10.1186/1471-2377-13-151. Access: abstract_metadata. Study: PREMiSe-NCT01450072.

50. Chambers B, Chambers J, Churilov L et al. Internal jugular and vertebral vein volume flow in patients with clinically isolated syndrome or mild multiple sclerosis and healthy controls: results from a prospective sonographer-blinded study. Phlebology. 2014. PMID 24065289. DOI: 10.1177/0268355513505505. Access: abstract_metadata. Study: MILD-CIS-possible-overlap.

51. Hojnacki D, Zamboni P, Lopez-Soriano A et al. Use of neck magnetic resonance venography, Doppler sonography and selective venography for diagnosis of chronic cerebrospinal venous insufficiency: a pilot study in multiple sclerosis patients and healthy controls. International angiology : a journal of the International Union of Angiology. 2010. PMID 20351669. DOI: none in PubMed record. Access: abstract_metadata. Study: PMID20351669.

52. Blinkenberg M, Akeson P, Sillesen H et al. Chronic cerebrospinal venous insufficiency and venous stenoses in multiple sclerosis. Acta neurologica Scandinavica. 2012. PMID 22530753. DOI: 10.1111/j.1600-0404.2012.01671.x. Access: abstract_metadata. Study: PMID22530753.

53. Simka M, Kostecki J, Zaniewski M et al. Extracranial Doppler sonographic criteria of chronic cerebrospinal venous insufficiency in the patients with multiple sclerosis. International angiology : a journal of the International Union of Angiology. 2010. PMID 20351666. DOI: none in PubMed record. Access: abstract_metadata. Study: PMID20351666.

54. Menegatti E, Genova V, Tessari M et al. The reproducibility of colour Doppler in chronic cerebrospinal venous insufficiency associated with multiple sclerosis. International angiology : a journal of the International Union of Angiology. 2010. PMID 20351668. DOI: none in PubMed record. Access: abstract_metadata. Study: PMID20351668.

55. Dolic K, Marr K, Valnarov V et al. Sensitivity and specificity for screening of chronic cerebrospinal venous insufficiency using a multimodal non-invasive imaging approach in patients with multiple sclerosis. Functional neurology. 2011. PMID 22364941. DOI: none in PubMed record. Access: abstract_metadata. Study: CTEVD-RESOURCE-possible-overlap.

56. Kantarci F, Albayram S, Demirci NO et al. Chronic cerebrospinal venous insufficiency: does ultrasound really distinguish multiple sclerosis subjects from healthy controls? European radiology. 2012. PMID 22124776. DOI: 10.1007/s00330-011-2338-5. Access: abstract_metadata. Study: PMID22124776.

57. Diaconu CI, Fox RJ, Grattan A et al. Hydration status substantially affects chronic cerebrospinal venous insufficiency assessments. Neurology. Clinical practice. 2013. PMID 24175155. DOI: 10.1212/CPJ.0b013e3182a78f15. Access: abstract_metadata. Study: PMID24175155.

58. Simka M, Ludyga T, Kazibudzki M et al. Multiple sclerosis, an unlikely cause of chronic cerebrospinal venous insufficiency: retrospective analysis of catheter venography. JRSM short reports. 2012. PMID 23301144. DOI: 10.1258/shorts.2011.010146. Access: abstract_metadata. Study: PMID23301144.

59. Lanzillo R, Mancini M, Liuzzi R et al. Chronic cerebrospinal venous insufficiency in multiple sclerosis: a highly prevalent age-dependent phenomenon. BMC neurology. 2013. PMID 23406210. DOI: 10.1186/1471-2377-13-20. Access: abstract_metadata. Study: PMID23406210.

60. Leone MA, Raymkulova O, Lochner P et al. Chronic cerebrospinal venous insufficiency is not associated with chronic venous disorders: A case-control study. Phlebology. 2015. PMID 25081746. DOI: 10.1177/0268355514544782. Access: abstract_metadata. Study: PMID25081746.

61. Weinstock-Guttman B, Ramanathan M, Marr K et al. Clinical correlates of chronic cerebrospinal venous insufficiency in multiple sclerosis. BMC neurology. 2012. PMID 22587224. DOI: 10.1186/1471-2377-12-26. Access: abstract_metadata. Study: CTEVD-RESOURCE-possible-overlap.

62. Bastianello S, Romani A, Viselner G et al. Chronic cerebrospinal venous insufficiency in multiple sclerosis: clinical correlates from a multicentre study. BMC neurology. 2011. PMID 22029656. DOI: 10.1186/1471-2377-11-132. Access: abstract_metadata. Study: PMID22029656.

63. Garaci FG, Marziali S, Meschini A et al. Brain hemodynamic changes associated with chronic cerebrospinal venous insufficiency are not specific to multiple sclerosis and do not increase its severity. Radiology. 2012. PMID 22915599. DOI: 10.1148/radiol.12112245. Access: abstract_metadata. Study: PMID22915599.

64. Zivadinov R, Cutter G, Marr K et al. No association between conventional brain MR imaging and chronic cerebrospinal venous insufficiency in multiple sclerosis. AJNR. American journal of neuroradiology. 2012. PMID 22576891. DOI: 10.3174/ajnr.A3112. Access: abstract_metadata. Study: CTEVD-RESOURCE-possible-overlap.

65. Zivadinov R, Schirda C, Dwyer MG et al. Chronic cerebrospinal venous insufficiency and iron deposition on susceptibility-weighted imaging in patients with multiple sclerosis: a pilot case-control study. International angiology : a journal of the International Union of Angiology. 2010. PMID 20351672. DOI: none in PubMed record. Access: abstract_metadata. Study: RRMS16-HC8-possible-overlap.

66. Zivadinov R, Poloni GU, Marr K et al. Decreased brain venous vasculature visibility on susceptibility-weighted imaging venography in patients with multiple sclerosis is related to chronic cerebrospinal venous insufficiency. BMC neurology. 2011. PMID 22011402. DOI: 10.1186/1471-2377-11-128. Access: abstract_metadata. Study: CTEVD-RESOURCE-possible-overlap.

67. Zakaria MMA, Mikhael SY, Hussein AKA et al. Failure of the vascular hypothesis of multiple sclerosis in a rat model of chronic cerebrospinal venous insufficiency. Folia neuropathologica. 2017. PMID 28430292. DOI: 10.5114/fn.2017.66713. Access: abstract_metadata. Study: PMID28430292.

68. Traboulsee AL, Knox KB, Machan L et al. Prevalence of extracranial venous narrowing on catheter venography in people with multiple sclerosis, their siblings, and unrelated healthy controls: a blinded, case-control study. Lancet (London, England). 2014. PMID 24119384. DOI: 10.1016/S0140-6736(13)61747-X. Access: abstract_metadata. Study: CANADIAN-DIAGNOSTIC.

69. Martin N, Traboulsee AL, Machan L et al. Prevalence of Extracranial Venous Narrowing on Magnetic Resonance Venography Is Similar in People With Multiple Sclerosis, Their Siblings, and Unrelated Healthy Controls: A Blinded, Case-Control Study. Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes. 2017. PMID 27887935. DOI: 10.1016/j.carj.2016.07.002. Access: abstract_metadata. Study: CANADIAN-DIAGNOSTIC.

Source-specific evidence cards

[1] Prospective randomized trial of venous angioplasty in MS (PREMiSe).

Shows: PREMiSe phase2 randomized 19 patients to venoplasty or sham; no clinical benefit and no sustained prespecified hemodynamic success in the randomized phase. Lesion and relapse counts trended adversely without significant between-arm differences.

Does not show: Small pilot, incomplete target engagement and exploratory analyses do not establish causal disease exacerbation. Linked erratum details were not supplied in PubMed and remain unchecked.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. ErratumIn: PMID not supplied in the PubMed record. Subclaims: SC3, SC4.

[2] Safety and efficacy of venoplasty in MS: A randomized, double-blind, sham-controlled phase II trial.

Shows: Canadian sham-controlled trial randomized 104 participants; primary MSQOL54 change and secondary clinical/MRI outcomes did not improve with venoplasty. Both arms had transient subjective improvement. One asymptomatic jugular dissection occurred after venoplasty.

Does not show: Only 60% planned power for the primary effect size and 48-week follow-up limit small/late effects. Serious adverse events occurred in 5 of 49 venoplasty and 1 of 55 sham participants; the blinded physician judged all six unrelated to the procedure, so they are not counted as procedural injury, but the arm imbalance is recorded.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 0:Methods:paragraph0, 0:Methods:paragraph4, 0:Methods:paragraph5, 0:Methods:paragraph6, 0:Methods:paragraph8, 1:Results:paragraph3, 1:Results:paragraph6, 1:Results:paragraph8, 1:Results:paragraph9, 1:Results:paragraph10. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC4.

[3] Efficacy and Safety of Extracranial Vein Angioplasty in Multiple Sclerosis: A Randomized Clinical Trial.

Shows: Brave Dreams randomized 115 RRMS patients; functional improvement and full-year MRI outcomes were not significantly better after angioplasty. Restored flow was observed in 38/71 treated and 14/37 sham participants; no procedure-attributed serious event occurred.

Does not show: Underrecruitment and incomplete engagement constrain an ideal-flow mechanism test. Favorable late MRI comparisons lost significance after multiplicity adjustment; clinical and MRI outcomes remain distinct.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Methods:paragraph2, 1:Methods:paragraph3, 1:Methods:paragraph5, 1:Methods:paragraph8, 1:Methods:paragraph11, 1:Methods:paragraph12, 1:Methods:paragraph13, 1:Methods:paragraph14, 2:Results:paragraph0, 2:Results:paragraph3, 2:Results:paragraph14, 2:Results:paragraph20, 2:Results:paragraph21. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC4.

[4] Effects of Venous Angioplasty on Cerebral Lesions in Multiple Sclerosis: Expanded Analysis of the Brave Dreams Double-Blind, Sham-Controlled Randomized Trial.

Shows: Expanded Brave Dreams analysis added 15 progressive patients; treated participants were more often free of new MRI lesions, RR 1.42, 95% CI 1.00–2.01, p = 0.032. Favorable venographic anatomy showed stronger post hoc MRI associations.

Does not show: Same randomized parent as 29150995, no independent clinical efficacy replication. Correction 31896294 explicitly labels classification post hoc; discordant classifications were excluded. MRI movement does not establish disability benefit.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Materials and Methods:paragraph0, 1:Materials and Methods:paragraph12, 1:Materials and Methods:paragraph13, 1:Materials and Methods:paragraph15, 1:Materials and Methods:paragraph16, 2:Results:paragraph0, 2:Results:paragraph1, 2:Results:paragraph3, 2:Results:paragraph4. No complete-paper or supplement audit claimed. ErratumIn: PMID31896294. Subclaims: SC3.

[5] Venous angioplasty in patients with multiple sclerosis: results of a pilot study.

Shows: Pilot immediate-versus-delayed venoplasty study of 15 RRMS patients reported functional improvement against baseline and nonsignificant relapse/MRI trends, with 27% restenosis at one year.

Does not show: Small nonsham comparison and baseline contrasts cannot separate expectation, natural fluctuation and treatment effect. Abstract design is case-control despite PubMed RCT label; no complete body audit.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC4.

[6] Percutaneous Venous Angioplasty in Patients with Multiple Sclerosis and Chronic Cerebrospinal Venous Insufficiency: A Randomized Wait List Control Study.

Shows: Randomized wait-list study of 66 participants found no objective evoked-potential or upper-limb kinematic improvement, while selected composite/QOL measures favored immediate treatment.

Does not show: No sham blinding; reported odds-ratio confidence interval is internally inconsistent in the abstract and is not treated as a verified quantitative effect.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[7] A prospective open-label study of endovascular treatment of chronic cerebrospinal venous insufficiency.

Shows: Open-label treatment of 65 MS patients lowered venous pressure and reported improved RRMS functional, relapse-free and MRI measures against baseline. Jugular patency was 53% versus 96% for the azygos vein.

Does not show: Uncontrolled treatment with high restenosis and subtype differences does not establish clinical causality; presumed first-series overlap is grouped conservatively. Linked erratum details remain unavailable.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. ErratumIn: PMID not supplied in the PubMed record. Subclaims: SC3, SC4.

[8] Endovascular treatment of CCSVI in patients with multiple sclerosis: clinical outcome of 462 cases.

Shows: Italian multicenter retrospective series of 462 treated patients found no significant disability improvement, relapses in 98 patients and 15 severe adverse events after treatment.

Does not show: No sham comparator and heterogeneous treatment; same parent as 23380649. Events occurring after treatment are not all established consequences of the procedure.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC4.

[9] Patient-Reported Benefits of Extracranial Venous Therapy: British Columbia CCSVI Registry.

Shows: British Columbia registry participants initially reported improvements after treatment, but these were not maintained at 24 months; self-reported complications were common enough to document a safety concern.

Does not show: Selection, recall, changing therapy and lack of blinded untreated controls prevent causal benefit/risk estimates.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC4.

[10] Medical Tourism for CCSVI Procedures in People with Multiple Sclerosis: An Observational Study.

Shows: Alberta cohort found disability, disease duration and progressive course associated with seeking out-of-country CCSVI procedures, directly identifying treatment-selection differences.

Does not show: A study of treatment-seeking selection does not estimate efficacy or procedural injury; it informs confounding rather than positive intervention tally.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[11] Endovascular treatment of chronic cerebrospinal venous insufficiency in multiple sclerosis: a retrospective study.

Shows: Retrospective follow-up of 45 RRMS patients found worse EDSS and more active MRI after venoplasty; 35.6% stopped disease-modifying treatment.

Does not show: Uncontrolled worsening, therapy discontinuation and indication confounding do not show angioplasty caused MS deterioration.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[12] An endovascular treatment of Chronic Cerebro-Spinal Venous Insufficiency in multiple sclerosis patients - 6 month follow-up results.

Shows: Small treatment cohort found no EDSS/ESS benefit, only transient QOL improvement and some fatigue/heat changes; restenosis and partial in-stent thrombosis occurred.

Does not show: Unblinded outcomes and selective subjective improvement do not establish disability efficacy. Balloon and stent risks are not interchangeable.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC4.

[13] Endovascular treatment of patients with chronic cerebrospinal venous insufficiency and multiple sclerosis.

Shows: Four treated cases reported early symptomatic and venographic improvement with no observed adverse events.

Does not show: Tiny uncontrolled case series cannot identify causal clinical benefit, durable patency or rare-event safety.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC4.

[14] Percutaneous transluminal angioplasty for chronic cerebrospinal venous insufficiency in multiple sclerosis: dichotomy between subjective and objective outcome scores.

Shows: Self-selected cohort of 44 patients reported improved QOL despite no relapse-rate benefit, worse EDSS and new MRI activity in some participants.

Does not show: Subjective/objective discordance is informative, but uncontrolled worsening cannot be attributed solely to venoplasty.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[15] Venous Hemodynamic Insufficiency Severity Score variation after endovascular treatment of chronic cerebrospinal venous insufficiency.

Shows: Follow-up of 45 treated patients found lower venous hemodynamic severity and modest baseline EDSS improvement; EDSS change did not differ between flow-responder groups.

Does not show: Post-treatment median-defined responders are not a prespecified causal subgroup; no sham comparator and p.746 responder contrast cannot validate mechanism mediation.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[16] Safety profile of endovascular treatment for chronic cerebrospinal venous insufficiency in patients with multiple sclerosis.

Shows: Series of 495 procedures in 461 MS patients documented venous rupture, dissection and eight stent or treated-segment thromboses, alongside no short-term death or major bleeding.

Does not show: Rates are procedure-denominated and setting-specific, mixing stents and balloons. Direct vascular injury supports possible procedural harm but not universal fatality.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4.

[17] Safety of endovascular treatment of chronic cerebrospinal venous insufficiency: a report of 240 patients with multiple sclerosis.

Shows: Thirty-day series of 257 procedures in 240 patients documented venous thromboses, prolonged arrhythmias and two hospitalizations, including stress cardiomyopathy during retreatment.

Does not show: Short follow-up and mixed techniques limit general incidence; reported temporal arrhythmia does not by itself prove every systemic event is catheter-caused.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4.

[18] Feasibility and safety of endovascular treatment for chronic cerebrospinal venous insufficiency in patients with multiple sclerosis.

Shows: Large procedural series recorded rupture requiring transfusion, groin bleeding requiring surgery, balloon-fragment retrieval and jugular thrombosis; complications clustered during earlier operator experience.

Does not show: Abstract has inconsistent patient denominators, so its exact incidence is not treated as verified. Mostly balloon treatment without jugular stenting maps a technique and learning-context boundary.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4.

[19] Endovascular diagnosis and management of chronic cerebrospinal venous insufficiency: retrospective analysis of 30-day morbidity and mortality in 95 consecutive patients.

Shows: Series of 107 procedures in 95 patients reported high technical success and three jugular thromboses, with no deaths within 30 days.

Does not show: Technical dilation success is not MS efficacy; short-term surveillance cannot exclude late injury. Linked correction concerns author spelling in the indexed notice.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. ErratumIn: PMID not supplied in the PubMed record. Subclaims: SC4.

[20] Adverse events after endovascular treatment of chronic cerebro-spinal venous insufficiency (CCSVI) in patients with multiple sclerosis.

Shows: Italian series reported 15 serious events among 462 treated patients at variable intervals, including seven jugular thromboses and a myocardial-infarction death ten weeks later.

Does not show: Same parent as 23354606. Temporal events including pneumonia or myocardial infarction are not all causally attributed; correction 28072565 was linked but blocked to body access, so corrected numerical details remain unverified.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. ErratumIn: PMID28072565. Subclaims: SC4.

[21] Internal jugular thrombosis post venoplasty for chronic cerebrospinal venous insufficiency.

Shows: A patient developed jugular thrombosis after balloon venoplasty without a stent despite anticoagulation, requiring surgical thrombectomy.

Does not show: Objective local mechanical complication supports a can-cause claim, not the frequency of injury or a causal MS-worsening estimate.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4.

[22] Endovascular treatment for chronic cerebrospinal venous insufficiency: is the procedure safe?

Shows: Procedural series documented two thrombotic stent occlusions and surgical femoral venotomy to retrieve an angioplasty balloon.

Does not show: Mixed balloon/stent exposure and short observation do not yield one universal liberation-therapy risk; mechanical failures can be causally linked within their settings.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4.

[23] Complications in MS patients after CCSVI procedures abroad (Calgary, AB).

Shows: Five referred patients after treatment abroad had complications including stent thrombosis, migration and catheter-related injury.

Does not show: Referral selection lacks a treated-population denominator; establishes examples of injury, not incidence across all providers.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4.

[24] Serious complication of percutaneous angioplasty with stent implantation in so called "chronic cerebrospinal venous insufficiency" in multiple sclerosis patient.

Shows: Case report documents stent displacement and thrombosis by imaging after repeated venous stenting, with subsequent worsening of disability.

Does not show: The paper discusses potential fatal embolism, not an observed fatal pulmonary embolus; disability deterioration has additional possible causes.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4.

[25] Spiral vein graft for internal jugular bypass in a patient with multiple sclerosis and suspected chronic cerebrospinal venous insufficiency.

Shows: Case report describes jugular stent thrombosis despite antithrombotic therapy, failed repeat intervention and later bypass graft occlusion.

Does not show: Specific device failure is observable; subjective symptom response does not establish MS disease modification or a general complication rate.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4.

[26] Chronic cerebrospinal venous insufficiency in patients with multiple sclerosis.

Shows: Foundational study found abnormal Doppler patterns in all 65 MS patients and none of selected controls, with venographic stenoses in screen-positive patients.

Does not show: Ultrasound was blinded, but invasive venography knew diagnosis and used ultrasound-positive selection plus controls undergoing venography for other illnesses; this is association, not temporal or causal proof.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 0:METHODS:paragraph0, 0:METHODS:paragraph3, 0:METHODS:paragraph4, 0:METHODS:paragraph6, 0:METHODS:paragraph9, 0:METHODS:paragraph22, 0:METHODS:paragraph23, 0:METHODS:paragraph24, 1:SELECTIVE VENOGRAPHY:paragraph0. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[27] The severity of chronic cerebrospinal venous insufficiency in patients with multiple sclerosis is related to altered cerebrospinal fluid dynamics.

Shows: Small 16-RRMS/8-control study associated venous severity with lower CSF flow.

Does not show: Cross-sectional physiology does not establish onset or treatment dependency; likely shared sample with 20351672, not independent mechanistic replication.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[28] Hemodynamic patterns of chronic cerebrospinal venous insufficiency in multiple sclerosis. Correlation with symptoms at onset and clinical course.

Shows: Venographic patterns in 65 CCSVI-positive MS patients were related to disease onset and course categories.

Does not show: Selected cases without a comparable healthy denominator cannot show MS specificity or prospective temporal order; conservatively grouped with first 65-patient series.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[29] Prevalence, sensitivity, and specificity of chronic cerebrospinal venous insufficiency in MS.

Shows: CTEVD found CCSVI more frequently in MS than healthy controls, but substantial control positivity and higher progressive-course frequency.

Does not show: Partial association with poor specificity does not establish primary causation; clinical subset and related imaging reports share recruitment resources.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[30] Observational case-control study of the prevalence of chronic cerebrospinal venous insufficiency in multiple sclerosis: results from the CoSMo study.

Shows: CoSMo multicenter blinded local/central reading found similar low CCSVI prevalence in MS, other neurodegenerative diseases and healthy controls, with low positive agreement.

Does not show: Diagnostic negative result concerns specified criteria and adjudication, not every vascular abnormality. Rare positives and operator disagreement bound sensitivity claims.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[31] Mystery of chronic cerebrospinal venous insufficiency: identical venographic and ultrasound findings in patients with MS and controls.

Shows: MS and controls showed similar ultrasound/venographic features; most venographed controls had at least 50% narrowing.

Does not show: Controls had other indications for venography and the MS cohort was small; common narrowing challenges specificity but does not by itself establish general-population prevalence.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[32] Chronic cerebrospinal venous insufficiency: masked multimodal imaging assessment.

Shows: Masked multimodal Houston study found discordant ultrasound/MRV findings and no clinically meaningful venographic pressure gradients in the examined subset.

Does not show: Same parent as 23418024; selective invasive subset and supine pressure measurements limit broader physiology. Anatomical narrowing alone is not functionally important obstruction.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Subjects and methods:paragraph4, 1:Subjects and methods:paragraph5, 2:Results:paragraph4. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[33] Chronic cerebrospinal venous insufficiency: case-control neurosonography results.

Shows: Blinded Houston assessment of 206 MS and 70 non-MS subjects found no excess CCSVI or venous-velocity abnormality in MS.

Does not show: Single-center recruitment and fixed criteria restrict generalization; companion multimodal report is the same study unit.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 0:Subjects and Methods:paragraph0, 0:Subjects and Methods:paragraph6, 1:Results:paragraph3, 1:Results:paragraph8, 1:Results:paragraph9. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[34] Doppler ultrasound examination of multiple sclerosis patients and control participants: inter-observer agreement and association with disease.

Shows: Blinded Finnish study found poor observer agreement and small jugular calibre more often in longstanding MS than controls, with weaker differences in recent MS.

Does not show: Cross-sectional duration differences permit secondary change or ageing; calibre association is not MS-specific flow causality.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[35] Chronic cerebrospinal venous insufficiency in multiple sclerosis: a sonographer-blinded case-control study.

Shows: Blinded study found no significant CCSVI case-control association while particular stenosis findings were more frequent in MS.

Does not show: Retains a positive anatomical result, but selective criterion differences and multiplicity do not validate the composite or causal mechanism.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[36] Chronic cerebrospinal venous insufficiency is not associated with multiple sclerosis and its severity: a blind-verified study.

Shows: Blind-verified study found CCSVI in 30.9% of MS patients and 33.8% of controls; experienced, specifically trained operators showed variable estimates.

Does not show: Blinding was successful in cases but imperfect in controls; single-study null does not show no vascular pathology, while training alone does not restore MS specificity.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Methods:paragraph0, 1:Methods:paragraph2, 1:Methods:paragraph10, 1:Methods:paragraph11, 2:Results:paragraph3, 2:Results:paragraph8, 2:Results:paragraph9. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[37] No association between chronic cerebrospinal venous insufficiency and pediatric-onset multiple sclerosis.

Shows: Blinded pediatric-onset MS study found no significant excess of CCSVI over controls.

Does not show: Small early-onset sample limits precision; nevertheless early disease can occur without detected composite abnormalities.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[38] MR venography in children and adolescents with multiple sclerosis does not show increased prevalence of extracranial veins anomalies.

Shows: Pediatric MR venography found venous anomalies at least as common in controls as childhood MS.

Does not show: Modest sample and imaging modality limit exclusion of subtle physiology; no proof of a necessary initiating venous lesion.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[39] Progressive multiple sclerosis is not associated with chronic cerebrospinal venous insufficiency.

Shows: Progressive MS case-control study found very few Doppler-positive cases and no relationship with disability; only one selected venographic participant had bilateral stenosis.

Does not show: Selective invasive confirmation and small positives limit sensitivity; absence of a detected abnormality is not exclusion of every vascular contribution.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[40] Chronic cerebrospinal venous insufficiency is not more prevalent in patients with mild multiple sclerosis: a sonographer-blinded, case-control ultrasound study.

Shows: Blinded study of mild MS/CIS matched pairs found the CCSVI composite in only one control; anatomical jugular differences depended on stenosis definition.

Does not show: Definition sensitivity and low-disability selection constrain general scope; grouped conservatively with related mild/CIS flow study 24065289.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[41] Prevalence of chronic cerebrospinal venous insufficiency in multiple sclerosis: a blinded sonographic evaluation.

Shows: Blinded M-mode-enhanced Doppler study found CCSVI in 59.8% of 112 MS patients and none of 67 controls.

Does not show: Important positive original remains contrary to other blinded studies; modality/protocol dependence and no prospective causal manipulation block universal specificity.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[42] Validity of the diagnostic criteria for chronic cerebrospinal venous insufficiency and association with multiple sclerosis.

Shows: Blinded ultrasound/MRV assessment found no significant composite CCSVI or patency difference between MS and controls.

Does not show: Composite criteria and modalities differed; a nonsignificant two-criterion frequency contrast is not proof of exact equivalence.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[43] Extracranial Venous Drainage Pattern in Multiple Sclerosis and Healthy Controls: Application of the 2011 Diagnostic Criteria for Chronic Cerebrospinal Venous Insufficiency.

Shows: Blinded revised-criteria Doppler study found no significant MS/control frequency difference.

Does not show: Small sample and alternative criteria limit sensitivity and equivalence inference.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[44] No evidence of chronic cerebrospinal venous insufficiency at multiple sclerosis onset.

Shows: CIS study found some ultrasound positives but no venographic abnormalities in the seven positive patients who underwent confirmation.

Does not show: Verification restricted to screen positives and small numbers; challenges necessity at early disease, not all possible venous physiology.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[45] Proposed chronic cerebrospinal venous insufficiency criteria do not predict multiple sclerosis risk or severity.

Shows: MS/healthy-control study found no significant CCSVI frequency difference or association with disability, course or progression.

Does not show: Modest cross-sectional sample cannot prove exact equivalence or establish a direction of causality.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[46] Multiple sclerosis and CCSVI: a population-based case control study.

Shows: Sicilian population case-control study found higher CCSVI frequency in MS, particularly progressive and longer-duration disease; CIS was not significantly different.

Does not show: Observational case-control design, despite RCT metadata label. Duration and progression associations permit consequence/ageing and do not establish temporal initiation.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[47] The fluctuating natural course of CCSVI in MS patients and controls, a prospective follow-up.

Shows: Prospective repeat assessment found some baseline CCSVI positives becoming negative and new positives without intervention.

Does not show: Fluctuating detection challenges a fixed diagnostic target; follow-up observational study is not a randomized treatment trial despite indexing.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[48] Centralized and Local Color Doppler Ultrasound Reading Agreement for Diagnosis of the Chronic Cerebrospinal Venous Insufficiency in Patients with Multiple Sclerosis.

Shows: Expert local and central blinded Doppler readings showed substantial overall agreement and high agreement for particular criteria.

Does not show: Both readers used shared acquired data; positive reader reproducibility is not independent acquisition reliability or proof of MS-specific causal obstruction.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Methods:paragraph0, 1:Methods:paragraph7, 1:Methods:paragraph11, 2:Results:paragraph3, 2:Results:paragraph4, 2:Results:paragraph5. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[49] Multimodal noninvasive and invasive imaging of extracranial venous abnormalities indicative of CCSVI: results of the PREMiSe pilot study.

Shows: PREMiSe diagnostic pilot found structural anomalies by venography/IVUS in selected ultrasound-positive candidates.

Does not show: Same trial parent as 24975855; screen-negative patients lacked invasive testing and no healthy-control denominator. Differential verification prevents specificity inference.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[50] Internal jugular and vertebral vein volume flow in patients with clinically isolated syndrome or mild multiple sclerosis and healthy controls: results from a prospective sonographer-blinded study.

Shows: Blinded mild/CIS jugular-flow study found no significant adjusted flow differences by diagnosis in supine/sitting measurements.

Does not show: Related recruitment to 22961213 grouped conservatively; measured flow does not exhaust every vascular mechanism.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[51] Use of neck magnetic resonance venography, Doppler sonography and selective venography for diagnosis of chronic cerebrospinal venous insufficiency: a pilot study in multiple sclerosis patients and healthy controls.

Shows: Small multimodal pilot found all ten MS participants Doppler-positive and seven controls negative, with lower MRV sensitivity.

Does not show: Only MS participants had venographic confirmation; tiny sample and differential verification prevent robust general specificity.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[52] Chronic cerebrospinal venous insufficiency and venous stenoses in multiple sclerosis.

Shows: Doppler/MRV/phase-contrast assessment found no participant meeting two CCSVI criteria and no significant MS/control flow difference.

Does not show: Small study supports diagnostic challenge, not exact exclusion of subtle flow differences.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[53] Extracranial Doppler sonographic criteria of chronic cerebrospinal venous insufficiency in the patients with multiple sclerosis.

Shows: Open-label series of 70 MS patients reported frequent extracranial ultrasound criteria.

Does not show: No healthy comparator or blinded discrimination; high prevalence alone cannot establish MS specificity.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[54] The reproducibility of colour Doppler in chronic cerebrospinal venous insufficiency associated with multiple sclerosis.

Shows: Training/retest study showed better operator agreement after CCSVI training and high same-operator repeat agreement.

Does not show: Small study with shared scanning system does not establish universal cross-center specificity; abstract confidence limits above one are not repeated as verified interval estimates.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[55] Sensitivity and specificity for screening of chronic cerebrospinal venous insufficiency using a multimodal non-invasive imaging approach in patients with multiple sclerosis.

Shows: Multimodal Doppler/MRV combinations improved specificity for selected CCSVI definitions in MS/control samples.

Does not show: Substantial control positivity, shared recruitment resources and criterion selection limit out-of-sample generalization; not causal MS evidence.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[56] Chronic cerebrospinal venous insufficiency: does ultrasound really distinguish multiple sclerosis subjects from healthy controls?

Shows: Case-control Doppler study found substantial overlap of venous criteria and mostly similar flow.

Does not show: Criterion-specific calibre differences are not a coherent causal obstruction or proof of no vascular role.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[57] Hydration status substantially affects chronic cerebrospinal venous insufficiency assessments.

Shows: Hydration challenge in 16 people changed CCSVI diagnostic classification, with most dehydrated positives losing status after fluid intake.

Does not show: Direct physiological sensitivity of measurement does not prove every positive diagnosis artifactual or test MS disease modification.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[58] Multiple sclerosis, an unlikely cause of chronic cerebrospinal venous insufficiency: retrospective analysis of catheter venography.

Shows: Retrospective venography in 353 patients found venous severity uncorrelated with disease duration.

Does not show: A lack of duration correlation does not prove congenital causation; selected treated/detected cases do not establish temporal precedence.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[59] Chronic cerebrospinal venous insufficiency in multiple sclerosis: a highly prevalent age-dependent phenomenon.

Shows: MS/control Doppler study reported high CCSVI prevalence associated strongly with age and poorly with clinical variables.

Does not show: Age-dependent association and diagnostic heterogeneity permit vascular ageing rather than primary MS causality.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[60] Chronic cerebrospinal venous insufficiency is not associated with chronic venous disorders: A case-control study.

Shows: Blinded study found no association between CCSVI classification and other chronic venous disease.

Does not show: Phenotype-specific negative association does not test MS therapeutic benefit or directly disprove brain venous effects.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[61] Clinical correlates of chronic cerebrospinal venous insufficiency in multiple sclerosis.

Shows: CTEVD clinical analysis associated CCSVI with progressive status but not broadly with disability or course severity.

Does not show: Same parent as 21490322; selected nominal associations and shared measures are not independent causal lines.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[62] Chronic cerebrospinal venous insufficiency in multiple sclerosis: clinical correlates from a multicentre study.

Shows: Six-center series reported high CCSVI prevalence and associations with progressive course and disability, with large center variation.

Does not show: No healthy-control denominator; site variation, age and duration confounding prevent specificity and primary-driver inference.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[63] Brain hemodynamic changes associated with chronic cerebrospinal venous insufficiency are not specific to multiple sclerosis and do not increase its severity.

Shows: Perfusion study found reduced cerebral blood volume/flow with CCSVI in MS and non-MS groups, while disability related to a different transit-time measure.

Does not show: Cross-sectional perfusion and nonspecific vascular effects do not establish MS-specific inflammation/progression causality.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[64] No association between conventional brain MR imaging and chronic cerebrospinal venous insufficiency in multiple sclerosis.

Shows: Brain MRI analysis found no convincing CCSVI association with conventional lesion or atrophy measures.

Does not show: Cross-sectional analysis cannot exclude a small longitudinal mechanism; related cohort resources do not form wholly independent evidence.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[65] Chronic cerebrospinal venous insufficiency and iron deposition on susceptibility-weighted imaging in patients with multiple sclerosis: a pilot case-control study.

Shows: Small 16-RRMS/8-control susceptibility MRI study associated iron measures with venous hemodynamic severity.

Does not show: Iron-sensitive imaging is a proxy and cross-sectional association cannot predict progression causally; grouped with 20018140.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[66] Decreased brain venous vasculature visibility on susceptibility-weighted imaging venography in patients with multiple sclerosis is related to chronic cerebrospinal venous insufficiency.

Shows: Susceptibility venography associated reduced vessel visibility with CCSVI in MS.

Does not show: Visibility depends on metabolism, blood oxygenation and imaging; does not directly demonstrate pressure obstruction or cause of MS.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[67] Failure of the vascular hypothesis of multiple sclerosis in a rat model of chronic cerebrospinal venous insufficiency.

Shows: Chronic jugular ligation in rats produced iron deposition and reactive gliosis, but no demyelination, axonal loss, inflammation or neurological weakness after eight months.

Does not show: Positive vascular tissue effects remain real. Severe artificial ligation and collateral anatomy differ from human CCSVI; this is a scoped sufficiency challenge, not proof that all vascular roles in MS are absent.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[68] Prevalence of extracranial venous narrowing on catheter venography in people with multiple sclerosis, their siblings, and unrelated healthy controls: a blinded, case-control study.

Shows: Blinded Canadian catheter-venography study found greater-than-50% narrowing similarly common in MS, unaffected siblings and unrelated controls; ultrasound poorly identified such narrowing.

Does not show: Anatomical narrowing is not validated pathological obstruction; incomplete invasive observations and fixed definitions bound generalization.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[69] Prevalence of Extracranial Venous Narrowing on Magnetic Resonance Venography Is Similar in People With Multiple Sclerosis, Their Siblings, and Unrelated Healthy Controls: A Blinded, Case-Control Study.

Shows: MRI companion study found extracranial narrowing common across MS, sibling and unrelated-control groups, with poor interreader and MRV/venography agreement.

Does not show: Same diagnostic parent as 24119384; different imaging readout adds assay information rather than independent population replication.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

Documentary record

Every grade on this site is reproducible from its record. The files below are the posted edition exactly as assessed.

• ADVERSARIAL_REVIEW.md
• CONSENSUS_CROSSCHECK.html
• CONSENSUS_CROSSCHECK.md
• RESEARCH_TIMELINE.html
• RESEARCH_TIMELINE.md
• SHA256.txt
• adversarial-findings.json
• ccsvi-ms-liberation.review.md
• ccsvi-ms-liberation.scorecard.json
• codex-correction-provenance.json
• consensus-validation.json
• edition-approval-audit.json
• reader-summary.json
• research-timeline.json
• validation-report.json
• validation-round2-2026-10-14.json
• validation.txt
• video-insert.md
• web-page.md

Sources: 69 · load-bearing claims: 74 · verified: 74 · unverified: 0 · contradicted: 0 · schema 5.3